Novavax(NVAX) stock is popping higher on news that its Covid-19 vaccine has been approved for use in American adults. The approval enables Novavax to begin commercial sales of shot Covid-19 shot in the U.S. Novavax comes to the vaccine party late with nearly 80% of adults in America already fully vaccinated. Novavax(NASDAQ:NVAX) stock is up 6% today after the U.S. Centers for Disease Control and Prevention (CDC) approved its two-dose Covid-19 vaccine for use in adults.TheCDC approvalpaves the way for Novavax to begin commercial sales of its long delayed Covid-19 vaccine in the U.S. This is an extremely positive development for the Gaithersburg, Maryland-based biotech company. Novavax has struggled with repeated delays regarding regulatory approval of its shot against the highly contagious